¿î¿µÀÚ ¿¬±¸¼Ò

¡Å ÀÌ°÷Àº ¾ÆÅäÇÇ¾Æ ¿î¿µÀÚ°¡ 20³â°£ÀÇ Ã¼Çè¿¡ ±âÃÊÇÏ¿© ¾ÆÅäÇÇ¿¡ ±Øº¹ ÆÁ°ú ÇØ¿ÜÃֽŠÁ¤º¸, ¿¬±¸ÀÚ·á ¹ø¿ª, Ä¡·áÁ¤º¸µîÀ» ½á³ª°¡´Â °÷ÀÔ´Ï´Ù. óÀ½¿À½Å ºÐµéÀº ºüÁü¾øÀÌ Àо½Ã±æ ¹Ù¶ø´Ï´Ù. ( º» ¿¬±¸¼ÒÀÇ ±ÛÀ» »çÀüÇã¶ô¾øÀÌ Àοë½Ã¿¡´Â ¹ýÀû Á¦À縦 ¹ÞÀ¸½Ç¼ö ÀÖ½À´Ï´Ù.)


ÀÚ·á¼ö : 244 °³, 9 ÆäÀÌÁöÁß 3 ÆäÀÌÁö Category
Á¦¸ñ : °¨ÀÙÂ÷ÀÇ ¾ÆÅäÇÇ ¿¹¹æ¹× Ä¡·áÈ¿°ú
 
µî·ÏÀÏ: 2004-06-21 14:26:41 , Á¶È¸: 5,602



¾ÆÅäÇǼº ÇǺο° ¸ðµ¨ ¸¶¿ì½ºÀÎ NC/NGA ¸¶¿ì½º¿¡°Ô °¨ÀÙÀ» ¸Ô¿´À»¶§ ³ªÅ¸³ª´Â ÇǺÎÁõ»óÀÇ °æ°¨È¿°ú¿Í ÇǺÎÀÇ ¼öºÐ ¼Õ½Ç °æ°¨È¿°ú.

Oral administration of persimmon leaf extract ameliorates skin symptoms and transepidermal water loss in atopic dermatitis model mice, NC/Nga.

Br J Dermatol. 2002 Feb; 146(2): 221-7.
Matsumoto M, Kotani M, Fujita A, Higa S, Kishimoto T, Suemura M, Tanaka T.

ÀϺ» ¿À»çÄ« ¿¬±¸¿Í °³¹ß ¼¾ÅÍ,
Research and Development Center, Sunstar Incorporation, Osaka, Japan.

¿¬±¸ ¹è°æ: ¿ì¸®´Â ÀÌÀü¿¡ °¨ÀÙ ÃßÃâ¹°¹× °¨ÀÙÀÇ Áֿ伺ºÐÀÎ ÈĶ󺸳ëÀÌµå ¼ººÐÀÎ ¾Æ½ºÆ®¶ó°¥¸°ÀÌ È£¿°±â±¸¸¦ ÅëÇÏ¿©¼­ È÷½ºÅ¸¹Î ºÐºñ¸¦ ¾ïÁ¦ÇÑ´Ù´Â °ÍÀ» º¸°íÇÏ¿´´Ù. ±×¸®°í ÀÌ°ÍÀ» ¾ÆÅäÇÇ À¯¹ßµÈ Áã¿¡°Ô ÀÔÀ¸·Î ¸Ô¿´À»¶§ ¾ÆÅäÇÇÀÇ ¿¹¹æ¿¡ µµ¿òÀÌ µÈ´Ù´Â°ÍÀ» º¸°íÇѹ٠ÀÖ´Ù.

¿¬±¸ ¸ñÇ¥: ÀÌ ¿¬±¸´Â °¨ÀÙÂ÷¿Í ±× ÁÖ¼ººÐÀÎ ¾Æ½ºÆ®¶ó °¥¸°ÀÇ ÀÓ»óÀû °¡Ä¡¸¦ Æò°¡ÇÏ°íÀÚ µðÀÚÀÎ µÇ¾ú´Ù. ¾ÆÅäÇÇ°¡ À¯¹ßµÈ ¸¶¿ì½º¿¡°Ô °¨ÀÙÂ÷¿Í ¾Æ½ºÆ®¶ó°¥¸°À» ¿ë·®À» ´Þ¸®ÇÏ¿© °¡¸é¼­ ¾ÆÅäÇÇ ÇǺλóÅÂ¿Í ÇǺÎÀÇ ¼öºÐ¼Õ½Ç»óŸ¦ Á¶»çÇÏ¿´´Ù.

¿¬±¸ ¹æ¹ý: ¾ÆÅäÇÇ À¯¹ßµÈ ¸¶¿ì½ºÀÇ ÇǺθ¦ ±Ü´Â Á¤µµ, Ç÷û³» IgE Á¤µµ, TEFL(ÇǺÎÀÇ ¼öºÐ¼Õ½Ç)À» ÃøÁ¤ÇÏ¿© °¨ÀÙÂ÷¿Í ¾Æ½ºÆ®¶ó°¥¸°ÀÇ È¿°ú¸¦ ÃøÁ¤ÇÏ¿´´Ù.

°á°ú: 4ÁÖµ¿¾ÈÀÇ °¨ÀÙÂ÷³ª ¾Æ½ºÆ®¶ó°¥¸°ÀÇ º¹¿ëÀº ¾ÆÅäÇÇ ¸¶¿ì½ºÀÇ ÇǺμջóÀ» ¸¹ÀÌ ¾ïÁ¦ÇÏ¿© ÁÖ¾ú´Ù.±×¸®°í ÀÌ·± ¾ïÁ¦È¿°ú´Â ¿ë·®¿¡ ºñ·ÊÇÏ¿© È¿°ú°¡ ³ªÅ¸³µ´Ù. ±×¸®°í ²ÙÁØÈ÷ °¨ÀÙÂ÷¸¦ º¹¿ëÇÏ¿´´õ´Ï ¾ÆÅäÇÇ Ãʱâ¹ßÇöÀ» ¾ïÁ¦ÇÏ°í ¾ÆÅäÇÇ·ÎÀÇ ¹ßÀüµÇ´Â°ÍÀ» ¾ïÁ¦ÇÏ¿´´Ù. °Ô´Ù°¡ ÇǺÎÀÇ ¼öºÐ¼Õ½Çµµ ¸¹ÀÌ °æ°¨½ÃÄÑÁÖ¾ú´Ù.
±×¸®°í ¶Ñ·ÇÇÑ ÀÌ»ó¹ÝÀÀÀº ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.

°á·Ð: ÀÌ·± °á°ú¸¦ ÅëÇؼ­ º¼¶§ °¨ÀÙÂ÷³ª ÀÌÀÇ ÁÖ¼ººÐÀÎ ¾Æ½ºÆ®¶ó °¥¸°Àº ¾ÆÅäÇǼº ÇǺο°ÀÇ °ü¸®¿¡ ¾ç¹æÄ¡·á¸¦ ´ëüÇÒ¸¸ÇÑ ÁÁÀº ¹°ÁúÀÌ µÉ°ÍÀ¸·Î º¸¿©Áø´Ù.

Oral administration of persimmon leaf extract ameliorates skin symptoms and transepidermal water loss in atopic dermatitis model mice, NC/Nga.

Br J Dermatol. 2002 Feb; 146(2): 221-7.
Matsumoto M, Kotani M, Fujita A, Higa S, Kishimoto T, Suemura M, Tanaka T.

BACKGROUND: We have previously shown that persimmon leaf extract and its major flavonoid constituent, astragalin, inhibited histamine release by basophils and that oral administration of these substances prior to the onset into an atopic dermatitis (AD) model mouse, NC/Nga, prevented development of dermatitis. OBJECTIVES: This study was designed to assess the clinical therapeutic effect of persimmon leaf extract and astragalin in NC/Nga mice suffering from dermatitis and the dose-response preventive effects of persimmon leaf extract on dermatitis and transepidermal water loss (TEWL). METHODS: The efficacy of persimmon leaf extract or astragalin in NC/Nga mice was judged by measurement of skin severity, scratching behaviour, serum IgE levels or TEWL. RESULTS: Oral administration of persimmon leaf extract (250 mg kg(-1)) or astragalin (1.5 mg kg-1) for 4 weeks into NC/Nga mice with overt dermatitis resulted in a decrease in the severity of the condition. The preventive effect of persimmon leaf extract on the dermatitis was dose-dependent and continuous intake of persimmon leaf extract significantly decreased its onset and development. In addition, TEWL was also suppressed at a persimmon leaf extract dose of 250 mg kg(-1). No significant adverse reaction by these substances could be observed. CONCLUSIONS: These observations suggest that persimmon leaf extract or the flavonoid astragalin may be alternative substances for the management of AD.

º» ±ÛÀº ³ë¾ÆÇÑÀÇ¿ø(http://www.atopynara.com)ÀÇ ÀÌÇü¼® ¿øÀå´Ô²²¼­ ¹ø¿ªÇÏ¿© Á¦°øÇØÁֽŠ±ÛÀÔ´Ï´Ù.


   



 
184  ÇÁ·ÎÅäÇÈ, ¿¤¸®µ¨ FDA ¹ßÇ¥¿¡ ´ëÇÑ ¹Ì±¹ÇǺΰúÇÐȸ ¼º¸í¼­ ¹ßÇ¥ 
1361 2005/03/18
183  [½ÄÇ°ÀǾàÇ°¾ÈÀüû] ¡°¿¤¸®µ¨ Å©¸²¡± ¹× ¡°ÇÁ·ÎÅäÇÈ ¿¬°í¡±¿¡ ´ëÇÑ ¾ÈÀü¼º ¼­ÇÑ ¹èÆ÷ 
1507 2005/03/16
182  ¿¤¸®µ¨°ú ÇÁ·ÎÅäÇÈ ¹ß¾Ï°¡´É¼º ¼Ò½Ä °ü·ÃÇÏ¿©... 
1493 2005/03/16
181  [¼Óº¸] ¿¤¸®µ¨°ú ÇÁ·ÎÅäÇÈ ¿¬°í ¾Ï¹ß»ý À§Çè - FDA ¹ßÇ¥ (25)
2160 2005/03/11
180  ±Ø´ÜÀûÀÎ ½Ä»çÁ¦ÇÑÀº À§Çè 
3852 2004/11/18
179  ¸é¿ªÇÐÀ¸·ÎºÎÅͺ» ¾ÆÅäÇÇÀÇ ±âº»Ä¡·á (4) 
4482 2004/11/12
178  ¸é¿ªÇÐÀ¸·ÎºÎÅͺ» ¾ÆÅäÇÇÀÇ ±âº»Ä¡·á (3) 
4211 2004/11/12
177  ¸é¿ªÇÐÀ¸·ÎºÎÅͺ» ¾ÆÅäÇÇÀÇ ±âº»Ä¡·á (2) 
5075 2004/11/12
176  ¸é¿ªÇÐÀ¸·ÎºÎÅͺ» ¾ÆÅäÇÇÀÇ ±âº»Ä¡·á (1) 
6154 2004/11/12
175  ÀÚÀ²½Å°æÁõ»ó ÀÚ°¡Å×½ºÆ® 
4740 2004/11/01
174  ÀÚÀ²½Å°æ Q&A 
5028 2004/11/01
173  ÀÚÀ²½Å°æ°ú ¾ÆÅäÇÇÀÇ °ü°è 
5494 2004/11/01
172  ¾ÆÅäÇÇ È¯ÀÚÀÇ 80% À̻󿡰Լ­ ³ªÅ¸³ª´Â ÀÚÀ²½Å°æ½ÇÁ¶Áõ 
6122 2004/11/01
171  ¾ÆÅäÇÇ¿Í °¡Á·°ü°è (3) 
4567 2004/10/18
170  ¾ÆÅäÇÇ¿Í °¡Á·°ü°è (2) 
5496 2004/10/18
169  ¾ÆÅäÇÇ¿Í °¡Á·°ü°è (1) 
5521 2004/10/18
168  ÀϺ» ¾Ë·¹¸£±â Á¤º¸¼¾ÅÍ Q&A 
5186 2004/10/07
167  Á¤Ã¼ºÒ¸íÀÇ Áß±¹Á¦ ¿¬°í¿¡´Â ÁÖÀǸ¦!!! 
4775 2004/09/01
166  ¸é ¿Ê¿¡ ³²¾ÆÀÖ´Â ¼¼Á¦°¡ °Ü¿ïö¿¡ ¾ÆÅäÇÇ ÇǺο°À» ¾ÇÈ­½Ãų ¼ö ÀÖ´Ù 
5063 2004/08/17
165  ¹«½ÃÇؼ­´Â ¾ÈµÉ ¾È°úÇÕº´Áõ (Á¤±â°ËÁø Áß¿ä) 
4974 2004/08/16
164  ¾ÆÅäÇÇȯÀÚ¿¡ ¾ÈÀüÇÑ Ãµ¿¬µÎ¹é½Å °³¹ß 
4946 2004/07/15
163  ¾ÆÅäÇǼҾƿ¡µµ ÀÏ¹Ý ¿¹¹æÁ¢Á¾Çؾߠ
6381 2004/07/15
162  BCG Á¢Á¾¿¡ ¾ÆÅäÇÇ ¿¹¹æÈ¿°ú ¾ø¾î (´ÖÄÉÀ̽Ź®) 
5170 2004/07/15
161  BCG¸¦ Á¢Á¾ÇÏ¸é ¾ÆÅäÇÇ°¡ Àß »ý±âÁö ¾Ê´Â´Ù??? 
4937 2004/07/15
160  ºÒ¼ÒÈ­ÀÇ À¯ÇØÀÛ¿ë¿¡ ´ëÇÑ °úÇÐ Âü°íÀÚ·á 
4624 2004/07/12
159  ºÒ¼ÒÈ­¸¦ ¹Ý´ëÇØ¾ß ÇÏ´Â 50°¡Áö ÀÌÀ¯ 
5360 2004/07/12
158  ¾ÆÀ̵éÀÇ ¾ÆÅäÇÇ¿Í ½É¸®ÀûÀÎ °ü°è 
4942 2004/07/12
 °¨ÀÙÂ÷ÀÇ ¾ÆÅäÇÇ ¿¹¹æ¹× Ä¡·áÈ¿°ú 
5602 2004/06/21
156  ±¹³» ¿¬±¸ÆÀ »õ·Î¿î ¾Ë·¹¸£±â Ä¡·á¿ë õ¿¬ ½Å¹°Áú °³¹ß 
5109 2004/05/31
155  À¯¾Æ±â Ç×»ýÁ¦ ³ëÃâ "¾ÆÅäÇǤýõ½Ä" Áõ°¡...Ú¸¿¬±¸ÆÀ 
4683 2004/05/11
[1][2] 3 [4][5][6][7][8][9]
 
Copyright 1999-2024 Zeroboard